Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$110.12 -2.0%	$106.51	$72.21 ▼ $139.13	$5.42B	0.46	668,031 shs	593,296 shs
BHVN Biohaven	$13.27 -6.5%	$15.94	$13.25 ▼ $55.70	$1.36B	0.91	1.31 million shs	1.62 million shs
LNTH Lantheus	$81.26 -2.2%	$80.26	$73.11 ▼ $126.89	$5.62B	0.12	972,654 shs	762,725 shs
RYTM Rhythm Pharmaceuticals	$89.36 +0.2%	$64.34	$40.61 ▼ $94.80	$5.69B	2.26	590,158 shs	852,323 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+3.07%	+4.49%	+7.91%	+8.19%	+35.62%
BHVN Biohaven	+2.10%	+2.69%	-8.06%	-23.60%	-62.77%
LNTH Lantheus	+2.15%	+4.89%	+6.72%	-19.19%	-32.70%
RYTM Rhythm Pharmaceuticals	+2.83%	+34.28%	+41.73%	+43.58%	+78.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7135 of 5 stars	4.5	1.0	4.5	2.2	4.2	0.6
BHVN Biohaven	3.0675 of 5 stars	4.5	1.0	0.0	1.7	2.5	0.6
LNTH Lantheus	4.5731 of 5 stars	3.5	2.0	4.2	2.5	2.5	1.9
RYTM Rhythm Pharmaceuticals	3.179 of 5 stars	2.5	1.0	4.3	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	56.50% Upside
BHVN Biohaven	3.07	Buy	$58.46	340.45% Upside
LNTH Lantheus	3.00	Buy	$131.20	61.46% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.00	1.84% Upside

Current Analyst Ratings Breakdown

Latest BHVN, LNTH, RYTM, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.06	N/A	N/A	$1.18 per share	93.32
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
LNTH Lantheus	$1.54B	3.66	$7.09 per share	11.46	$15.65 per share	5.19
RYTM Rhythm Pharmaceuticals	$130.13M	43.69	N/A	N/A	$0.35 per share	255.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.05	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	23.09	12.88	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest BHVN, LNTH, RYTM, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
BHVN Biohaven	N/A	2.33	2.33
LNTH Lantheus	0.49	5.74	5.46
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BHVN Biohaven	88.78%
LNTH Lantheus	99.06%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
BHVN Biohaven	14.60%
LNTH Lantheus	2.00%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

BHVN, LNTH, RYTM, and AXSM Headlines

Recent News About These Companies

Analysts Set Expectations for RYTM Q4 Earnings

July 15 at 8:23 AM | marketbeat.com

Q2 EPS Estimate for Rhythm Pharmaceuticals Lifted by Analyst

July 15 at 2:12 AM | americanbankingnews.com

Leo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 14 at 9:16 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $3,389,817.60 in Stock

July 14 at 4:13 AM | americanbankingnews.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 15,572 Shares of Stock

July 14 at 4:13 AM | americanbankingnews.com

Leerink Partnrs Issues Optimistic Outlook for RYTM Earnings

July 14 at 2:23 AM | marketbeat.com

Alps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

July 13 at 4:44 AM | marketbeat.com

Bank of America Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13 at 2:27 AM | americanbankingnews.com

Wells Fargo & Company Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

July 13 at 2:27 AM | americanbankingnews.com

The Goldman Sachs Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 13 at 2:27 AM | americanbankingnews.com

Oppenheimer Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

July 13 at 2:27 AM | americanbankingnews.com

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12 at 6:00 PM | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - Nasdaq

July 12 at 8:15 AM | nasdaq.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of Stock

July 12 at 6:15 AM | insidertrades.com

Q2 Earnings Forecast for RYTM Issued By Leerink Partnrs

July 12 at 2:17 AM | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 3,817 Shares

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $619,828.82 in Stock

July 11, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 15,572 Shares

July 11, 2025 | marketbeat.com

Hunter C. Smith Sells 42,120 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

July 11, 2025 | marketbeat.com

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

July 11, 2025 | msn.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $95.00

July 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, LNTH, RYTM, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$110.12 -2.21 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$110.10 -0.03 (-0.02%)

As of 04:30 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Biohaven NYSE:BHVN

$13.27 -0.92 (-6.46%)

Closing price 03:59 PM Eastern

Extended Trading

$13.46 +0.18 (+1.37%)

As of 04:53 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Lantheus NASDAQ:LNTH

$81.26 -1.80 (-2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$78.17 -3.09 (-3.80%)

As of 04:56 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.36 +0.21 (+0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$89.36 0.00 (0.00%)

As of 04:24 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time